Analysts forecast that United Therapeutics Corporation (NASDAQ:UTHR) will report sales of $430.87 million for the current quarter, according to Zacks. Six analysts have provided estimates for United Therapeutics Corporation’s earnings, with estimates ranging from $415.90 million to $442.51 million. United Therapeutics Corporation posted sales of $408.20 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 5.6%. The business is scheduled to issue its next earnings results on Thursday, October 26th.

According to Zacks, analysts expect that United Therapeutics Corporation will report full-year sales of $430.87 million for the current fiscal year, with estimates ranging from $1.59 billion to $1.72 billion. For the next financial year, analysts expect that the business will report sales of $1.38 billion per share, with estimates ranging from $1.22 billion to $1.55 billion. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for United Therapeutics Corporation.

United Therapeutics Corporation (NASDAQ:UTHR) last released its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of $3.61 by ($4.86). The company had revenue of $444.60 million for the quarter, compared to the consensus estimate of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The business’s revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the company posted $4.42 EPS.

UTHR has been the subject of several recent analyst reports. ValuEngine cut shares of United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, June 2nd. Jefferies Group LLC reaffirmed a “sell” rating and issued a $105.00 target price on shares of United Therapeutics Corporation in a report on Thursday, June 8th. BidaskClub raised shares of United Therapeutics Corporation from a “strong sell” rating to a “sell” rating in a report on Friday, June 9th. UBS AG reaffirmed a “sell” rating and issued a $106.00 target price on shares of United Therapeutics Corporation in a report on Thursday, July 6th. Finally, Zacks Investment Research cut shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Six investment analysts have rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $134.50.

In other news, Director Christopher Causey sold 580 shares of the business’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $134.48, for a total transaction of $77,998.40. Following the completion of the transaction, the director now directly owns 3,295 shares of the company’s stock, valued at $443,111.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Raymond Dwek sold 3,490 shares of the business’s stock in a transaction that occurred on Friday, June 23rd. The shares were sold at an average price of $131.71, for a total transaction of $459,667.90. The disclosure for this sale can be found here. Insiders have sold 25,178 shares of company stock valued at $3,289,427 over the last three months. 7.80% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in UTHR. BlackRock Inc. grew its position in United Therapeutics Corporation by 4,222.8% during the first quarter. BlackRock Inc. now owns 4,741,985 shares of the biotechnology company’s stock valued at $641,969,000 after buying an additional 4,632,287 shares during the period. Wells Fargo & Company MN grew its position in United Therapeutics Corporation by 144.0% during the second quarter. Wells Fargo & Company MN now owns 730,634 shares of the biotechnology company’s stock valued at $94,785,000 after buying an additional 431,210 shares during the period. JPMorgan Chase & Co. grew its position in United Therapeutics Corporation by 308.6% during the second quarter. JPMorgan Chase & Co. now owns 500,499 shares of the biotechnology company’s stock valued at $64,930,000 after buying an additional 378,002 shares during the period. AQR Capital Management LLC grew its position in United Therapeutics Corporation by 27.8% during the first quarter. AQR Capital Management LLC now owns 1,736,357 shares of the biotechnology company’s stock valued at $235,068,000 after buying an additional 377,395 shares during the period. Finally, Renaissance Technologies LLC grew its position in United Therapeutics Corporation by 65.5% during the second quarter. Renaissance Technologies LLC now owns 837,600 shares of the biotechnology company’s stock valued at $108,662,000 after buying an additional 331,400 shares during the period.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2017/09/13/430-87-million-in-sales-expected-for-united-therapeutics-corporation-uthr-this-quarter.html.

United Therapeutics Corporation (UTHR) traded down 0.16% during trading on Friday, hitting $123.18. The company had a trading volume of 456,444 shares. United Therapeutics Corporation has a one year low of $110.90 and a one year high of $169.89. The stock has a 50-day moving average of $129.61 and a 200-day moving average of $130.11. The stock has a market capitalization of $5.35 billion, a PE ratio of 14.29 and a beta of 1.52.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Get a free copy of the Zacks research report on United Therapeutics Corporation (UTHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.